JPMorgan lowered the firm’s price target on Genmab (GMAB) to DKK 1,500 from DKK 1,700 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab reports ‘encouraging anti-tumor activity’ for Rina-S in Phase 1/2 trial
- Genmab Continues Share Buy-back Program Amid Strategic Financial Management
- Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
- Genmab Executes Share Buy-back Transactions in May 2025
- Genmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results